Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19278553 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL26159269 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL18581608 | 0.79 | HDAC1 (0.65) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL25058874 | 0.78 | HDAC1 (0.68) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL23950277 | 0.76 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL23950274 | 0.76 | HDAC1 (0.72) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1366170 | 0.76 | HDAC6 (0.61) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL20879365 | 0.76 | HDAC1 (0.85) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL18581862 | 0.75 | HDAC1 (0.60) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL23950282 | 0.75 | HDAC6 (0.64) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4137483-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Zhongze Therapeutics, Co. Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-113527206-B | Benzoazaheterocycle compound, preparation method and application thereof | 上海中泽医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-113527206-A | Benzoazaheterocycle compound, preparation method and application thereof | 上海中泽医药科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021208945-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海中泽医药科技有限公司 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HDAC11, HDAC1, HDAC6 | HDAC1 2/4885HDAC6 3/4885HDAC8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.